Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis

• Published in: Surgical oncology Vol. 28; pp. 228 - 235
• Main Authors: Wong, Tiffany CL, Chiang, Chi-Leung, Lee, Ann-Shing, Lee, Victor HF, Yeung, Cynthia SY, Ho, Connie HM, Cheung, Tan-To, Ng, Kelvin KC, Chok, Siu-Ho, Chan, Albert CY, Dai, Wing-Chiu, Wong, Frank CS, Luk, Mai-Yee, Leung, To-Wai, Lo, Chung-Mau
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.03.2019; Elsevier Limited
• Subjects: Abdomen; Demographics; Demography; Disease; Disease control; Hepatitis; Hepatocellular carcinoma; Hospitals; Liver cancer; Matching; Medical prognosis; Metastasis; Multivariate analysis; Outcomes; Patients; Radiation; Radiation therapy; Stereotactic body radiation therapy; Survival; Toxicity; Transarterial chemoembolization; Tumors; Unresectable; Unresectable; Hepatocellular carcinoma; Stereotactic body radiation therapy; Transarterial chemoembolization; Outcomes
• ISSN: 0960-7404; 1879-3320; 1879-3320
• DOI: 10.1016/j.suronc.2019.01.006

This study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body radiation therapy (SBRT) after TACE (TACE + SBRT). This was a retrospective study of 2 centers in Hong Kong. There were 49 patients who had TACE + SBRT and 202 patients who had TACE alone. Propensity score matching was used to adjust for differences in patients’ demographics and tumor characteristics between the 2 groups. The primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS) and treatment-related toxicity. After matching, 49 patients were in the TACE + SBRT group and 98 patients in the TACE group with similar baseline characteristics. The 1-&3-year OS were better in TACE + SBRT group (67.2 vs. 43.9% and 36.5 vs. 13.3%, p = 0.003). The 1-&3-year PFS was also better in TACE + SBRT group (32.5 vs. 21.4% and 15.1 vs. 5.1%, p = 0.012). Radiological disease control was better in the TACE + SBRT group (98 vs. 56.7%). Risk of severe toxicity was uncommon in both treatment arms. TACE + SBRT was an independent good prognostic factor for OS and PFS in multivariate analysis, whereas AFP>200 ng/ml, large tumor and multiple tumors predicted worse OS. TACE + SBRT is safe and results in better survivals in nonresectable HCC patients.